Clinical Trial Update: Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab [Phase 2]

View source ↗

Summary

A Phase II lymphoma trial evaluating fludarabine and mitoxantrone followed by GM-CSF and rituximab was terminated. Results from the study have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Fludarabine (Fludarabine)
• GM-CSF (Granulocyte-macrophage colony-stimulating factor) (granulocyte-macrophage colony-stimulating factor)
• Mitoxantrone (mitoxantrone)
• Rituximab (rituximab)

Snippet

Sponsor: Emory University | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2012-06-28